858 Therapeutics Announces $50 Million Series B Financing

Sep 26, 2024  · 858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae


Install CouponFollow Chrome Extension   CouponFollow Extension

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

Sep 26, 2024  · 858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae

businesswire.com

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

Sep 27, 2024  · “The Series B financing is a testament to the 858 team and the progress we’ve made across our portfolio, including the advancement of our PARG inhibitor ETX-19477 into …

biospace.com

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

SAN DIEGO, September 26, 2024--858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset …

yahoo.com

$50
OFF

858 Therapeutics Secures $50M Series B Financing To Advance …

6 days from now

Oct 3, 2024  · 858 Therapeutics raises $50M in Series B financing led by Avidity Partners. Proceeds to advance ETX-19477, a selective PARG inhibitor for cancer treatment. Phase 1 …

sliceofhealthcare.com

$50
OFF

858 Therapeutics Raises $50M In Series B Financing Round

6 days from now

Sep 27, 2024  · Funds will be used to advance a Phase I trial of 858's PARG inhibitor ETX-19477 in advanced solid tumors. ... 858 Therapeutics Raises $50M in Series B Financing Round Sep …

precisionmedicineonline.com

$50
OFF

858 Therapeutics Raises $50 Million In Series B Funding To …

6 days from now

Sep 26, 2024  · 858 Therapeutics has secured $50 million in a Series B funding round led by Avidity Partners, with participation from Insight Partners, Mirae Asset Capital, and Alexandria …

siliconvalleyjournals.com

$50
OFF

858 Therapeutics Nabs $50M Round - San Diego Business Journal

6 days from now

Oct 14, 2024  · LA JOLLA– Torrey Pines-based 858 Therapeutics has successfully raised $50 million in Series B financing to advance its pipeline of small molecule drugs that target cancer …

sdbj.com

$50
OFF

858 Therapeutics Raises $50M In Series B Financing - Finsmes.com

6 days from now

Sep 27, 2024  · 858 Therapeutics, a San Diego, CA-based biotechnology and drug discovery company, raised $50M in Series B funding.. The round was led by Avidity Partners with …

finsmes.com

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

Oct 10, 2024  · September 26, 2024 08:00 AM Eastern Daylight Time. SAN DIEGO–(BUSINESS WIRE)–858 Therapeutics today announced it raised $50 million in a Series B financing led by …

intelligence360.news

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

SAN DIEGO, September 26, 2024-- 858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset …

vcaonline.com

$50
OFF

858 Therapeutics: Drug Discovery Company Raises $50 Million …

6 days from now

Sep 28, 2024  · 858 Therapeutics announced it raised $50 million in a Series B financing led by Avidity Partners. Participation came from Insight Partners, Mirae Asset Capital, and Alexandria …

pulse2.com

$50
OFF

858 Therapeutics Secures $50M Series B Funding

6 days from now

Sep 30, 2024  · SAN DIEGO—858 Therapeutics has successfully secured $50 million in a Series B funding round. The financing was spearheaded by Avidity Partners and saw contributions …

patsnap.com

$50
OFF

858 Therapeutics Secures $50 Million In Series B Funding

6 days from now

Sep 27, 2024  · San Diego start-up 858 Therapeutics has raised $50 million in a Series B round led by Avidity Partners, with participation from new and existing investors. The funds will …

thepharmaletter.com

$50
OFF

858 Therapeutics Secures $50M In Series B Round For Innovations

6 days from now

Sep 26, 2024  · 858 Therapeutics has successfully raised $50 million in a Series B financing to advance their innovative pipeline of small molecule therapeutics for cancer treatment. ... 858 …

investorshangout.com

$50
OFF

858 Therapeutics Secures $50 Million In Series B Funding To …

6 days from now

858 Therapeutics, an innovative biotechnology and drug discovery company specializing in oncology, has successfully raised $50 million in its latest funding round. This significant capital …

leadsontrees.com

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

Sep 26, 2024  · SAN DIEGO — 858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset …

financialpost.com

$50
OFF

858 Therapeutics Raises $50 Million In Series B Funding To Advance ...

6 days from now

Sep 26, 2024  · 858 Therapeutics has raised $50 million in a Series B financing round led by Avidity Partners, involving other investors. This funding will be used to progress the …

bio-research.ai

$50
OFF

Drug Discovery Company Raises $50 Million (Series B)

6 days from now

Sep 29, 2024  · The Series B funding is a testament to the 858 team and the progress we have made across our portfolio, including advancing our PARG inhibitor ETX-19477 into the clinic.”-Jeffrey Stafford, Ph.D., CEO of 858 Therapeutics “858 Therapeutics has an experienced management team with a track record of treating challenging targets.

mukujapaneseramen.ca

$50
OFF

858 Therapeutics Announces $50 Million Series B Financing

6 days from now

Sep 26, 2024  · 858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset Capital, and …

wedbush.com

FAQs about 858 Therapeutics Announces $50 Million Series B Financing Coupon?

Who financed 858 Therapeutics?

SAN DIEGO, September 26, 2024 -- (BUSINESS WIRE)--858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments, as well as existing investors Versant Ventures, NEA, and Logos Capital. ...

Why did 858 get a series B financing?

"The Series B financing is a testament to the 858 team and the progress we’ve made across our portfolio, including the advancement of our PARG inhibitor ETX-19477 into the clinic." 858 Therapeutics plans to use the proceeds to advance its pipeline of small molecule therapeutics. ...

Did avidity raise $50 million in a series B financing?

SAN DIEGO, September 26, 2024--858 Therapeutics today announced it raised $50 million in a Series B financing led by Avidity Partners with participation from Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments, as well as existing investors Versant Ventures, NEA, and Logos Capital. ...

Who is joining 858 Therapeutics' Board of directors?

As part of the financing, Monal Mehta, Ph.D., Managing Director at Avidity Partners, will join the company’s Board of Directors. "We are pleased to have strong backing from an elite group of life science investors," said Jeffrey Stafford, Ph.D., CEO of 858 Therapeutics. ...

What will 858 Therapeutics do with etx-19477?

858 Therapeutics plans to use the proceeds to advance its pipeline of small molecule therapeutics. The company’s lead asset, ETX-19477, is a potent and selective inhibitor of the DNA repair protein PARG and is currently being evaluated in patients with advanced solid tumors. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension